Vireo Growth (VREOF) Cash & Equivalents (2020 - 2026)
Vireo Growth (VREOF) reported Cash & Equivalents of $137.8 million for Q1 2026, up 59.86% on a YoY basis from $86.2 million in Q1 2025, and up 12.49% sequentially from $122.5 million in Q4 2025.
Vireo Growth (VREOF) Cash & Equivalents (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Cash & Equivalents data on file, last reported at $137.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents rose 59.86% year-over-year to $137.8 million; the trailing twelve-month figure through Mar 2026 stood at $137.8 million (up 59.86% YoY), and the FY2025 full-year result was $122.5 million, up 33.73% from the prior year.
- Cash & Equivalents advanced to $137.8 million in Q1 2026, from $122.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $137.8 million in Q1 2026 to a low of $7.3 million in Q3 2024.
- A 5-year average of $47.0 million and a median of $16.0 million in 2023 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents tumbled 78.79% in 2022 and surged 1514.58% in 2025, its largest moves.
- Tracing VREOF's Cash & Equivalents over 5 years: stood at $15.1 million in 2022, then rose by 5.38% to $16.0 million in 2023, then soared by 473.77% to $91.6 million in 2024, then soared by 33.73% to $122.5 million in 2025, then increased by 12.49% to $137.8 million in 2026.
- Business Quant data shows VREOF's Cash & Equivalents at $137.8 million in Q1 2026, $122.5 million in Q4 2025, and $117.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 137.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137.80 Mn |
| Dec 31, 2025 | 122.50 Mn |
| Sep 30, 2025 | 117.54 Mn |
| Jun 30, 2025 | 99.13 Mn |
| Mar 31, 2025 | 86.20 Mn |
| Dec 31, 2024 | 91.60 Mn |
| Sep 30, 2024 | 7.28 Mn |
| Jun 30, 2024 | 11.23 Mn |
| Mar 31, 2024 | 12.60 Mn |
| Dec 31, 2023 | 15.96 Mn |
| Sep 30, 2023 | 13.30 Mn |
| Jun 30, 2023 | 11.35 Mn |
| Mar 31, 2023 | 10.35 Mn |
| Dec 31, 2022 | 15.15 Mn |
| Sep 30, 2022 | 21.84 Mn |
| Jun 30, 2022 | 16.97 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 15.16 Mn |
| Sep 30, 2021 | 11.78 Mn |
| Jun 30, 2021 | 20.83 Mn |